| Literature DB >> 28913878 |
Daniele Campa1, Manuela Pastore1,2, Gabriele Capurso3, Thilo Hackert4, Milena Di Leo5, Jakob R Izbicki6, Kay-Tee Khaw7, Domenica Gioffreda8, Juozas Kupcinskas9, Claudio Pasquali10, Peter Macinga11, Rudolf Kaaks12, Serena Stigliano3, Petra H Peeters13,14, Timothy J Key15, Renata Talar-Wojnarowska16, Pavel Vodicka11, Roberto Valente3, Yogesh K Vashist6,17, Roberto Salvia18, Ioannis Papaconstantinou19, Yasuhiro Shimizu20, Chiara Valsuani21, Carlo Federico Zambon22, Maria Gazouli23, Irena Valantiene9, Willem Niesen4, Beatrice Mohelnikova-Duchonova24, Kazuo Hara25, Pavel Soucek26, Ewa Malecka-Panas16, H B As Bueno-de-Mesquita27,28,29, Theron Johnson12, Herman Brenner30,31,32, Francesca Tavano8, Paola Fogar33, Hidemi Ito34,35, Cosimo Sperti10, Katja Butterbach30, Anna Latiano8, Angelo Andriulli8, Giulia Martina Cavestro5, Olivier R C Busch36, Frederike Dijk37, William Greenhalf38, Keitaro Matsuo34,35, Carlo Lombardo39,40, Oliver Strobel4, Anna-Katharina König4, Katarina Cuk30, Hendrik Strothmann4, Verena Katzke12, Maurizio Cantore21, Andrea Mambrini21, Martin Oliverius41, Raffaele Pezzilli42, Stefano Landi1, Federico Canzian2.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less than 6%. Chronic pancreatitis (CP), an inflammatory process in of the pancreas, is a strong risk factor for PDAC. Several genetic polymorphisms have been discovered as susceptibility loci for both CP and PDAC. Since CP and PDAC share a consistent number of epidemiologic risk factors, the aim of this study was to investigate whether specific CP risk loci also contribute to PDAC susceptibility. We selected five common SNPs (rs11988997, rs379742, rs10273639, rs2995271 and rs12688220) that were identified as susceptibility markers for CP and analyzed them in 2,914 PDAC cases, 356 CP cases and 5,596 controls retrospectively collected in the context of the international PANDoRA consortium. We found a weak association between the minor allele of the PRSS1-PRSS2-rs10273639 and an increased risk of developing PDAC (ORhomozygous = 1.19, 95% CI 1.02-1.38, p = 0.023). Additionally all the SNPs confirmed statistically significant associations with risk of developing CP, the strongest being PRSS1-PRSS2-rs10273639 (ORheterozygous = 0.51, 95% CI 0.39-0.67, p = 1.10 × 10-6 ) and MORC4-rs 12837024 (ORhomozygous = 2.07 (1.55-2.77, ptrend = 0.7 × 10-11 ). Taken together, the results from our study do not support variants rs11988997, rs379742, rs10273639, rs2995271 and rs12688220 as strong predictors of PDAC risk, but further support the role of these SNPs in CP susceptibility. Our study suggests that CP and PDAC probably do not share genetic susceptibility, at least in terms of high frequency variants.Entities:
Keywords: Chronic pancreatitis; association; genetic polymorphisms; pancreatic ductal adenocarcinoma
Mesh:
Substances:
Year: 2017 PMID: 28913878 DOI: 10.1002/ijc.31047
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396